Average 22.5%↓in one and a half years
Despite the announcement of a drop in drug prices in 2018, the cost of single-use eye drops will be lowered from the September 5th, 2020. They maintained their existing prices for nearly two years through a lawsuit.
The Ministry of Health & Welfare announced on the 4th that the suspension of the notice of the list of drug benefits and the upper limit of benefits would terminate from the 5th.
The first division of the Supreme Court on the 3rd declared to terminate the suspension of the price reduction on the eight companies’ 33 single-use eye drops. The Ministry of Health & Welfare explained that there would be no further instruction in this regard.
The 33 products are ▲five Kynex3 Eye Drops (Huons) ▲seven Rebliss Eye Drops (Huons Medicare) ▲one Hyalsan Eye Drops (Daewoo Pharma) ▲two Eyehyal Eye Drops (SinSin Pharma) ▲five Aluen Eye Drops (YoungIl Pharma) ▲two Alron Eye Drops (Reyon Pharma) ▲two HyalQ Eye Drop (Il Dong Pharma) ▲one Fumelon Eye Drops ▲one Solcorin Eye Drops ▲five Hyaluronmax Eye Drops ▲one Hyaluron Eye Drops ▲one Fumelon Plus Eye Suspension (mentioned above are Hanlim Pharma).
As a result, the price cap for Kynex3 Eye Drops will be reduced by 3.9%~51.0% depending on capacity, Rebliss Eye Drop 13.6%~27.1%, Hyalsan 31.0%, Eyehyal 31.0%~33.1%, and Aluen 13.6%~31.1%.
The price of Alron Eye Drops will be lowered 15.5%~17.8%, HyalQ Eye Drop 26.1%~31.0%, Fumelon Eye Drops 4.3%, Solcorin Eye Drops 5.3%, Hyaluronmax Eye Drops 24.4%~32.8%, Hyaluron Eye Drops 31.0%, and Femelon Plus Eye Suspension 5.6%.
Meanwhile, the price cap of 0.9mg/0.3mL of Rebliss 0.3% Eye drops was decreased to KRW 371 (September 1, 2019), lower than what announcement said on December 21, 2018.